lipolysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
ADAM (A Database of Anti-Microbial peptides) Archived 2015-06-17 at the Wayback Machine at ntou.edu.tw AntiFP Prediction of antifungal peptides AntiMPmod Prediction of antimicrobial potential of modified peptides Antimicrobial+Cationic+Peptides at the U.S. National Library of Medicine Medical Subject Headings (MeSH) AntiTbPred Prediction of anti-tuberculosis peptides Antimicrobial Peptide Database Archived 2011-07-20 at the Wayback Machine at University of Nebraska Medical Center Antimicrobial Peptide Scanner Deep Learning based AMP prediction server AntiTbPdb Anti Tubercular Peptide Database BioPD[link removed] at Peking University Health Science Center CAMP:Collection of Anti-Microbial Peptides at National Institute for Research in Reproductive Health (NIRRH) DBAASP - Database of Antimicrobial Activity and Structure of Peptides] LAMP at Fudan University PeptideLocator Prediction of functional peptides, including antimicrobial peptides, in a protein sequence PeptideRanker Bioactive peptide, including antimicrobial peptide, prediction modlAMP Python package for computational work with antimicrobial peptides, including sequence handling, -design, -prediction, descriptor calculation and plotting
=== Sampling calorimeters for detectors in high-energy particle physics === Depleted uranium has been used in a number of sampling calorimeters (such as in the D0 and ZEUS detectors) because of its high density and natural radioactivity.
Plutonium-241 is a beta emitter with a half-life of 14.33 years, corresponding to a decay of about 5% of 241Pu nuclei over a one-year period. This decay has a Q-value of only 20.8 keV, and does not emit gamma rays. The longer spent nuclear fuel waits before reprocessing, the more 241Pu decays to americium-241, which is nonfissile (although fissionable by fast neutrons) and an alpha emitter with a half-life of 432.6 years; 241Am, which does emit gamma rays, is a major contributor to the radioactivity of nuclear waste on a scale of hundreds to thousands of years. In its fully ionized state, the beta-decay half-life of 241Pu94+ decreases to 4.2 days, and only bound-state beta decay is possible. Plutonium-241 also has a rare alpha decay branch to uranium-237, occurring in about 0.0025% of decays. Unlike its usual beta decay, this can emit gamma rays, X-rays, and associated electrons.
== Campaign == The campaign for was unusually short, lasting only seven weeks after the vote was brought forward from May to 18 March following negotiations between the Round Table and the government of Hans Modrow on 28 January. This tight schedule posed significant organizational challenges. Only the PDS, as the successor to the SED, possessed the necessary infrastructure and financial resources for a full campaign. In contrast, newly formed opposition parties and civil rights groups were still defining their platforms and had minimal experience in electioneering. Their shortcomings were partially mitigated by substantial support from West German parties, which provided logistical and strategic assistance to their Eastern counterparts. Western support facilitated the creation of several electoral alliances. The CDU partnered with the German Social Union and Democratic Awakening to form the Alliance for Germany. The FDP backed the Association of Free Democrats, which included the Liberal Democratic Party of Germany (LDPD) and the minor FDP of the GDR. These alliances were established only weeks before the election, relying heavily on Western assistance such as the CDU's "district partnerships" and the participation of West German campaigners. At the outset, the SPD appeared likely to win, benefiting from historical roots in the region and strong backing from the West German SPD. Early polls showed it leading with 54 percent support, ahead of the PDS and CDU. Despite early advantages, the SPD's momentum declined as reunification became the dominant issue.
=== Pseudobulbar affect === Pseudobulbar affect (PBA) is a condition involving episodic uncontrollable laughter or crying. PBA mostly occurs in people with neurological injuries affecting how the brain controls emotions. Scientists believe PBA results from prefrontal cortex damage. PBA often involves crying. Hence, PBA is mistakable for depression. But PBA is neurological; depression is psychological. Patients with PBA do not experience typical depression symptoms like sleep disturbances or appetite loss.
Sources: en.wikipedia.org
Cape Verde, Curaçao, Jordan, and Uzbekistan made their World Cup debuts. Qatar qualified for the tournament through qualification for the first time, as its only previous appearance was as host in 2022. DR Congo and Haiti returned to the tournament after appearing in their only previous tournament in 1974. Iraq returned to the tournament after appearing in its only previous tournament in 1986. Austria, Norway, and Scotland returned to the tournament after last appearing in 1998. Four-time champion Italy failed to qualify after losing the European playoff final to Bosnia and Herzegovina on penalties, becoming the first former champion to miss three consecutive World Cups; as in 2018 and 2022, Italy was the only former champion that did not qualify. With a FIFA Men's World Ranking of 12, Italy was also the highest-ranking team that did not qualify. The qualified teams, listed by region, with numbers in parentheses indicating final positions in the FIFA Men's World Ranking before the tournament were:
== External links == "Papers of John B. Fenn, 1948–2010 (bulk 1970–1990)". Science History Institute. Click on 'Fenn Papers Finding Aid 2014' for finding aid to archive. Interview where John Fenn discusses the history of the development of the Electrospray Ionization method Annual Reviews Conversations Interview with John B. Fenn (video) John B. Fenn on Nobelprize.org including the Nobel Lecture December 8, 2002 Electrospray Wings for Molecular Elephants Dudley R. Herschbach and Charles E. Kolb, "John B. Fenn", Biographical Memoirs of the National Academy of Sciences (2014)
=== 1996–2004: Hiatus, side projects and death of Layne Staley === Although Alice in Chains never officially disbanded, Staley became a recluse, rarely leaving his Seattle condominium following the death of his ex-fiancée Demri Parrott on October 29, 1996. "Drugs worked for me for years," Staley told Rolling Stone in February 1996, "and now they're turning against me ... now I'm walking through hell and this sucks. I didn't want my fans to think that heroin was cool. But then I've had fans come up to me and give me the thumbs up, telling me they're high. That's exactly what I didn't want to happen." Unable to continue with new Alice in Chains material, Cantrell released his first solo album, Boggy Depot, in 1998, also featuring Sean Kinney and Mike Inez. Cantrell and Kinney were also featured on Metallica's 1998 album Garage Inc., both were guest musicians in the track "Tuesday's Gone", a Lynyrd Skynyrd cover. In October 1998, Staley reunited with Alice in Chains to record two new songs, "Get Born Again" and "Died". Originally intended for Cantrell's second solo album, the songs were reworked by Alice in Chains and were released in the fall of 1999 on a box set, Music Bank. The set contains 48 songs, including rarities, demos, and previously released album tracks and singles. The band also released a 15-track compilation titled Nothing Safe: Best of the Box, serving as a sampler for Music Bank, as well as the band's first compilation album; a live album, simply titled Live, released on December 5, 2000; and a second compilation, titled Greatest Hits in 2001.
== Products and markets == Vacuum technology has always been an important utility in the production of electronics. The first TV and radio technologies emerged in the 1920s and 1930s, and Edwards Vacuum delivered vacuum pumps for the production of valve amplifiers, which enabled transmission and reception. In its initial years, Edwards Vacuum imported vacuum equipment from Germany's Leybold. A freeze-drying method using vacuum chambers was patented in the 1930s. During World War II, the technology was further perfected and expanded to freeze-dry instant coffee, but also blood plasma and penicillin. Penicillin itself was also produced using vacuum technology. World War II marked an acceleration in technological development for vacuum technology. Vacuum pump manufacturers innovated their products and new applications for vacuum emerged. This included but wasn't limited to, the development of radar transmitters and receivers used in operations, glass coating of binoculars and windscreens, infrared systems, used for night flying and operations, foil coating, which confused radar systems and the introduction of freeze-drying to remove moisture, applied to various pharmaceutical processes.
Sources: en.wikipedia.org
ribonuclease (RNase) Any of a class of nuclease enzymes which catalyze the hydrolytic cleavage of phosphodiester bonds in RNA molecules, thus severing polymeric strands of ribonucleotides into smaller components. Compare deoxyribonuclease.
=== 2017: Two Masters titles, world No. 3 === During the 2017 season, Zverev greatly improved his results at the higher level tournaments on the ATP Tour except for the four major events. It was at this time Zverev, who had been using his nickname Sascha, stated in a postmatch interview with Pam Shriver, that he would no longer be referred to as Sascha. Zverev stated that only his close family can refer to him as Sascha, as he was born in Germany and identifies as a German, and does not want a Russian nickname to be used for his professional career. At the Australian Open, Zverev again pushed Rafael Nadal to the brink, but ultimately lost in five sets. His next ATP tournament was the Open Sud de France, where he won both the singles and doubles events. He and his brother defeated Fabrice Martin and Daniel Nestor for Alexander's first doubles title. The following month, he made his first Masters quarterfinal at the Miami Open, upsetting No. 3 Stan Wawrinka along the way. Nick Kyrgios defeated him at both Masters events that month. After a slow start to the clay court season, Zverev won two more titles in May, the first of which came at home in Germany at the Bavarian International Tennis Championships. He then followed up a second Masters quarterfinal at the Madrid Open with his first Masters title at the Rome Masters. He defeated Novak Djokovic in the final to become the youngest Masters champion since Djokovic in 2007 and the first such champion born in the 1990s. With the title, he also entered the top 10 for the first time.
In the initial phase of Germany's invasion of the Soviet Union, Cossack émigrés were initially barred from political activity or travelling into the occupied Eastern territories. Hitler had no intention of entertaining the political aspirations of the Cossacks, or any minority group, in the USSR. As a result, collaboration between Cossacks and the Wehrmacht began in ad hoc manner through localized agreements between German field commanders and Cossack defectors from the Red Army. Hitler did not officially sanction the recruitment of Cossacks and lift the restrictions imposed on émigrés until the second year of the Nazi-Soviet conflict. During their brief occupation of the North Caucasus region, the Germans actively recruited Cossacks into detachments and local self-defense militias. The Germans even experimented with a self-governing district of Cossack communities in the Kuban region. When the Wehrmacht withdrew from the North Caucasus region in early 1943, tens of thousands of Cossacks retreated with them, either out of conviction or to avoid Soviet reprisals. In 1943, the Germans formed the 1st Cossack Cavalry Division, under the command of General Helmuth von Pannwitz. While its ranks mostly comprised deserters from the Red Army, many of its officers and NCOs were Cossack émigrés who had received training at one of the cadet schools established by the White Army in Yugoslavia. The division was deployed to occupied Croatia to fight Tito's Partisans. There, its performance was generally effective, although at times brutal.
Se8 + 24 F2 → 8 SeF6 In comparison with its sulfur counterpart (sulfur hexafluoride), selenium hexafluoride (SeF6) is more reactive and is a toxic pulmonary irritant. Selenium tetrafluoride is a laboratory-scale fluorinating agent. The only stable chlorides are selenium tetrachloride (SeCl4) and selenium monochloride (Se2Cl2), which might be better known as selenium(I) chloride and is structurally analogous to disulfur dichloride. Metastable solutions of selenium dichloride can be prepared from sulfuryl chloride and selenium (reaction of the elements generates the tetrachloride instead), and constitute an important reagent in the preparation of selenium compounds (e.g. Se7). The corresponding bromides are all known, and recapitulate the same stability and structure as the chlorides. The iodides of selenium are not well known, and for a long time were believed not to exist. There is limited spectroscopic evidence that the lower iodides may form in bi-elemental solutions with nonpolar solvents, such as carbon disulfide and carbon tetrachloride; but even these appear to decompose under illumination. Some selenium oxyhalides—seleninyl fluoride (SeOF2) and selenium oxychloride (SeOCl2)—have been used as specialty solvents.
Many types of MNPs have been developed to penetrate tissues other than skin, such as internal tissues of the mouth and digestive tract. These promote faster and more direct delivery of the molecule to the targeted area.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.